1,846 results on '"Italiano, Antoine"'
Search Results
2. Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
3. New strategies in soft tissue sarcoma treatment
4. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
5. Integration of pre-treatment computational radiomics, deep radiomics, and transcriptomics enhances soft-tissue sarcoma patient prognosis
6. Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients
7. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide
8. Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study
9. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA
10. Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study
11. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
12. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.
13. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
14. Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
15. Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
16. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
17. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
18. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
19. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
20. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
21. New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
22. Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
23. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
24. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
25. Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor
26. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
27. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
28. Diagnosis and management of TRK fusion cancer.
29. EWSR1::WT1 Fusions in Neoplasms Other Than Conventional Desmoplastic Small Round Cell Tumor: Three Tumors Occurring Outside the Female Genital Tract
30. Distinct patterns of the natural evolution of soft tissue sarcomas on pre-treatment MRIs captured with delta-radiomics correlate with gene expression profiles
31. Prognostic factors of the synovial sarcoma of the extremities: imaging does matter
32. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer
33. Radiomics and artificial intelligence for soft-tissue sarcomas: Current status and perspectives
34. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
35. Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
36. High dose (54 Gy) pre-operative helical tomotherapy for retroperitoneal liposarcoma: Results of a phase II multicenter study
37. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data
38. Structures lymphoïdes tertiaires : de la biogenèse à l’impact thérapeutique en cancérologie
39. Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers
40. A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl)
41. Utilisation des tests génomiques en oncologie : avis d’experts Français selon la méthode Delphi
42. Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022
43. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age
44. Développement des CAR-T cells dans les tumeurs solides
45. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
46. ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
47. Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
48. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT
49. Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study
50. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.